Abstract 5995
Background
The number of publications on the invasive fungal diseases caused by rare pathogens (rare IFD) after HSCT and chemotherapy is limited.
Methods
From 2008 to 2017 in R. Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation (CIC725) have been performed 2738 HSCT including 1845 allogeneic (allo-HSCT) and 893 autologous HSCT (auto-HSCT). During the observation period 40 probable and proven rare IFD (EORTC/MSG 2008 criteria) cases were diagnosed in children and adults with hematological malignances and non-malignant hematological diseases after allo-HSCT (n = 30), auto-HSCT (n = 2), and chemotherapy (n = 8). The median follow up time for rare IFD cases was 3 months; for survivors – 30 months.
Results
Incidence of rare IFD in HSCT recipients was 1,5%, it was higher after allo-HSCT (1,6%) than auto-HSCT (0,2%) (p < 0,01). In 8 patients, this complication developed after CT and 4 of them proceed to allo-HSCT. The most frequent underlying diseases were ALL (33%) and acute AML (30%). The median time of onset of rare IFD after allo-HSCT - 104 (21-1057) days, auto-HSCT – 138 (60-216), after start of CT – 161 (79-189). Etiology of rare IFD was identified by culture in 65% cases: Rhizopus spp. – 27%, Paecilomyces spp. – 7%, Fuzarium spp. – 5%, Malassezia furfur – 5%, Trichosporon asahii – 3%, Scedosporium apiosperium – 2%, Scopulariopsis gracilis – 2%, Rhizomucor pusillus – 2%, Lichtheimia corymbifera – 2%, mix rare IFD with Rhizopus spp. + Paecilomyces spp. – 5%, Paecilomyces spp. + Fuzarium spp. – 5%. 35% cases were diagnosed by microscopy. Antifungal therapy was used in all patients: lipid amphotericin B (L-AmB) – 30%, L-AmB + caspofungin – 22,5%, voriconazole – 17,5%, posaconazole (posa) – 12,5%, L-AmB + posa – 10%, and echinocandins – 7,5%. Overall survival at 12 weeks from the diagnosis of rare IFD was 50%. The 12-weeks overall survival was better in patients after CT and auto-HSCT (80%) than allo-HSCT (42%), p = 0,048.
Conclusions
The incidence of rare IFD in HSCT recipients was 1,5%. Rare IFD is a late complication after chemotherapy and HSCT and usually develops after or in combination with invasive aspergillosis. Higher incidence and worst prognosis rare IFD is observed in allo-HSCT recipients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5037 - CXCR4, CCR2 and CCR5 expression in subsets of tumor cells with stem and/or EMT features
Presenter: Olga Savelieva
Session: Poster Display session 1
Resources:
Abstract
5729 - Expression of mutant p53 affects cancer cell sensitivity to topotecan
Presenter: Rimma Mingaleeva
Session: Poster Display session 1
Resources:
Abstract
5725 - Breast cancer organoids a new tool for the prediction of drugs penetration and patient’outcome
Presenter: Giuseppina Roscigno
Session: Poster Display session 1
Resources:
Abstract
5680 - Aptamer-mediated exosomes detection for early breast cancer identification.
Presenter: Cristina Quintavalle
Session: Poster Display session 1
Resources:
Abstract
2460 - MicroRNA-181c promotes tamoxifen resistance in breast cancer cells via upregulation Akt/mTOR axis
Presenter: Alexander Scherbakov
Session: Poster Display session 1
Resources:
Abstract
3751 - Spatio-temporal separation of tumor infiltrating CD8+ T-cells and HER2/neu+ tumor cells in tumor-immune milieu of infiltrating ductal carcinoma of the breast
Presenter: Sandhya Sreedharan
Session: Poster Display session 1
Resources:
Abstract
4664 - Large genomic rearrangements in BRCA1 and BRCA2 genes in the Portuguese population.
Presenter: Joao Pinto
Session: Poster Display session 1
Resources:
Abstract
4611 - Non-BRCA1/2 hereditary breast and ovarian cancer: findings from a multidisciplinary program
Presenter: Ana Monteiro
Session: Poster Display session 1
Resources:
Abstract
5340 - Quantitative imaging and characterization of collagen patterns in high grade serous ovarian carcinoma (HGSOC)
Presenter: Ruby Huang
Session: Poster Display session 1
Resources:
Abstract
4209 - Semiquantitative assessment of vimentin expression in prostate cancer (PC)
Presenter: Marina Puchinskaya
Session: Poster Display session 1
Resources:
Abstract